PRODUCT INFORMAT



Sennoside A

Item No. 24969

CAS Registry No.:	81-27-6	
Formal Name:	(9R,9'R)-5,5'- <i>bis</i> (β-D-glucopyranosyloxy)-	
	9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-	
	dioxo-[9,9'-bianthracene]-2,2'-dicarboxylic acid	HC
Synonym:	NSC 112929	
MF:	$C_{42}H_{38}O_{20}$	
FW:	862.7	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 204 nm	нu.,
Supplied as:	A crystalline solid	но
Storage:	-20°C	
Stability:	≥4 years	н
Item origin:	Plant/Sennae folium	



Laboratory Procedures

Sennoside A is supplied as a crystalline solid. A stock solution may be made by dissolving the sennoside A in the solvent of choice, which should be purged with an inert gas. Sennoside A is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of sennoside A in these solvents is approximately 2 and 1 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of sennoside A can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of sennoside A in PBS (pH 7.2) is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Sennoside A is a dianthrone glycoside with laxative and gastroprotective activities.^{1,2} Ex vivo, sennoside A (30 mg/kg) increases the amplitude of distal colon contractions in circular and longitudinal muscle and decreases the amplitude of proximal colon contractions in circular muscle in mice.¹ Sennoside A (100 mg/kg, oral) increases the gastric emptying rate by 71.1% compared to control and increases the intestinal transport rate of a charcoal meal from 61.2 to 81.1% in mice.² It increases the concentration of prostaglandin E₂ (PGE₂; Item No. 14010) in AGS gastric cells in a dose-dependent manner in vitro. Intraduodenal administration of sennoside A (100 mg/kg) increases gastric juice pH and decreases gastric juice secretion volume and total acid output in pylorus-ligated rats. It also reduces lesion indices by 43.1 and 36% in HCI/ethanol-induced gastritis and indomethacin-induced gastric ulcer rat models, respectively, when administered at a dose of 100 mg/kg. Sennoside A is also a non-competitive inhibitor of bovine serum monoamine oxidase in vitro (IC₅₀ = 17 μ M).³ Formulations containing sennoside A have been used to treat constipation and to aid in evacuation of the bowel prior to surgery or invasive colonic or rectal examinations.

References

- 1. Kobayashi, M., Yamaguchi, T., Odaka, T., et al. Basic Clin. Pharmacol. Toxicol. 101(2), 121-126 (2007).
- 2. Hwang, I.Y. and Jeong, C.S. Biomol. Ther. (Seoul) 23(5), 458-464 (2015).
- 3. Hiraoka, A., Koike, S., Sakaguchi, S., et al. Chem. Pharm. Bull. (Tokyo) 37(10), 2744-2746 (1989).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cavman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information uyer agrees to purchase the material can be found on our website

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM